Evidence map›Paper›PMID 29442211›Full record

ArticleAnnals of surgical oncology2018

Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.

Colin M Court, Jacob S Ankeny, Shonan Sho, Paul Winograd, Shuang Hou, Min Song, Zev A Wainberg, Mark D Girgis, Thomas G Graeber, Vatche G Agopian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Implications of Heterotypic Cell Fusion in Cancer.Advances in experimental medicine and biology · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Circulating tumor cells in pancreatic cancer: more than liquid biopsy.Therapeutic advances in medical oncology · 2024
    Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Colin M CourtDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Jacob S AnkenyDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Shonan ShoDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Paul WinogradDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Shuang HouDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Min SongDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Zev A WainbergDepartment of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Mark D GirgisDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Thomas G GraeberDepartment of Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, CA, USA.
Vatche G AgopianDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
James S TomlinsonDepartment of Surgery, University of California Los Angeles, Los Angeles, CA, USA. jtomlinson@mednet.ucla.edu.

Funding

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
CTC Purification System Based on Thermoresponsive NanoSubstratesR44CA180482 · NCI · CYTOLUMINA TECHNOLOGIES CORPORATION, INC · PI LIU, SEAN XIAO, TSENG, HSIAN-RONG · 2015 to 2016
$2.0M
Molecular and Functional Analysis of Single Circulating Melanoma CellsR33CA174562 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2015
$987k
Advanced Development of An Integrated CTC Enrichment TechnologyR33CA157396 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2011 to 2013
$672k
Jonsson Cancer Center Foundation Impact GrantNational Institutes of Health R33 CA174562National Institutes of Health R44 CA180482National Institutes of Health U01 CA198900NCI NIH HHS R33 CA157396NCI NIH HHS R33 CA174562NCI NIH HHS R44 CA180482NCI NIH HHS U01 CA198900
6 · The paper itself

Abstract

backgroundOccult metastatic tumors, below imaging thresholds, are a limitation of staging systems that rely on cross-sectional imaging alone and are a cause of the routine understaging of pancreatic ductal adenocarcinomas (PDACs). We investigated circulating tumor cells (CTCs) as a preoperative predictor of occult metastatic disease and as a prognostic biomarker for PDAC patients. EXPERIMENTAL

designA total of 126 patients (100 with cancer, 26 with benign disease) were enrolled in our study and CTCs were identified and enumerated from 4 mL of venous blood using the microfluidic NanoVelcro assay. CTC enumeration was correlated with clinicopathologic variables and outcomes following both surgical and systemic therapies.

resultsCTCs were identified in 78% of PDAC patients and CTC counts correlated with increasing stage (ρ = 0.42, p < 0.001). Of the 53 patients taken for potentially curative surgery, 13 (24.5%) had occult metastatic disease intraoperatively. Patients with occult disease had significantly more CTCs than patients with local disease only (median 7 vs. 1 CTC, p < 0.0001). At a cut-off of three or more CTCs/4 mL, CTCs correctly identified patients with occult metastatic disease preoperatively (area under the receiver operating characteristic curve 0.82, 95% confidence interval (CI) 0.76-0.98, p < 0.0001). CTCs were a univariate predictor of recurrence-free survival following surgery [hazard ratio (HR) 2.36, 95% CI 1.17-4.78, p = 0.017], as well as an independent predictor of overall survival on multivariate analysis (HR 1.38, 95% CI 1.01-1.88, p = 0.040).

conclusionsCTCs show promise as a prognostic biomarker for PDAC patients at all stages of disease being treated both medically and surgically. Furthermore, CTCs demonstrate potential as a preoperative biomarker for identifying patients at high risk of occult metastatic disease.

Indexed as

AgedBiomarkers, TumorCarcinoma, Pancreatic DuctalFemaleFollow-Up StudiesHumansLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplastic Cells, CirculatingPancreatectomyPancreatic NeoplasmsPeritoneal NeoplasmsBiomarkers, Tumor

Identifiers

PMID29442211
PMCPMC5896564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.